News

Published on 11 Jan 2024 on Benzinga via Yahoo Finance

Cancer Cell Therapy Focused Marker Therapeutics Announces Pipeline Prioritization

Article preview image

Marker Therapeutics Inc (NASDAQ: MRKR) announced it is restructuring its clinical programs and strategic prioritization of its multi-tumor associated antigen (multiTAA)-specific T cell product pipeline.

The company has prioritized MT-601 in chimeric antigen receptor (CAR) relapse patients with lymphoma.

Read the rest of the article
NASDAQ.MRKR price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Marker Therapeutics Leads 3 Noteworthy US Penny Stocks

As the U.S. stock market takes a breather from its recent rally, investors are keenly watching fo...

Simply Wall St. · via Yahoo Finance 6 Dec 2024
Cancer Cell Therapy Focused Marker Therapeutics Announces Pipeline Prioritization

Marker Therapeutics Inc (NASDAQ: MRKR) announced it is restructuring its clinical programs and st...

Benzinga via Yahoo Finance 11 Jan 2024
Marker Therapeutics Inc's Uncertain Future: Understanding the Barriers to Outperformance

Long-established in the Biotechnology industry, Marker Therapeutics Inc (NASDAQ:MRKR) has enjoyed...

GuruFocus.com via Yahoo Finance 25 Aug 2023
EXCLUSIVE: Cancer Firm Plus Therapeutics Licenses Diagnostic Assay To Detect Central Nervous System...

Plus Therapeutics Inc (NASDAQ: PSTV) has expanded its supply agreement with Biocept Inc (NASDAQ: ...

Benzinga via Yahoo Finance 24 Aug 2023
Marker Therapeutics (NASDAQ:MRKR) hikes 26% this week, taking one-year gains to 95%

These days it's easy to simply buy an index fund, and your returns should (roughly) match the mar...

Simply Wall St. via Yahoo Finance 22 Jul 2023
Denali (DNLI) Provides Update on Hunter Syndrome Study

Denali Therapeutics DNLI announced positive interim results of the ongoing phase I/II study of DN...

Zacks via Yahoo Finance 1 Jul 2023
TScan Therapeutics Shares Fall After Preliminary Data Highlight In Leukemia Patients

TScan Therapeutics Inc (NASDAQ: TCRX) announced a poster presentation highlighting preliminary da...

Benzinga via Yahoo Finance 27 May 2023
Study reveals mechanism by which a circadian clock molecule leads to lung fibrosis

Abnormal sleep patterns, like those of night-shift workers, disrupt the body's natural biological...

Medical Xpress 17 Apr 2023
Merck-Moderna vaccine helps reduce chances of skin cancer

A vaccine launched by Merck and Moderna was found to reduce the chances of skin cancer when used...

The Hill 16 Apr 2023
eFFECTOR Therapeutics Collaborates With Stanford Medicine Mid-Stage Breast Cancer Study

eFFECTOR Therapeutics Inc (NASDAQ: EFTR) will collaborate with Stanford Medicine on an investigat...

Benzinga via Yahoo Finance 11 Apr 2023

Copyright Statfolio @ 2025

Social Accounts